In a randomized, double-blind trial of 108 treatment-seeking patients with alcohol use disorder and obesity, once-weekly semaglutide significantly reduced heavy drinking days compared with placebo over 26 weeks, alongside improvements in multiple alcohol-related outcomes. Gastrointestinal adverse events were more common with semaglutide but were generally mild to moderate and transient.

Source: The Lancet